title: [Suppressing effect of the serotonin 5HT1B/D receptor agonist rizatriptan on calcitonin gene-related peptide (CGRP) concentration in migraine attacks].
abstract: Calcitonin gene-related peptide (CGRP) is one of the neuropeptides most abundant in the nervous tissue. Recent studies indicate that local cranial release of CGRP from the trigeminal nerve perivascular endings within arachnoidea plays an important role in the pathophysiology of migraine attacks and cluster headaches. Elevated CGRP levels in cranial venous blood (in the jugular vein) during an acute spontaneous migraine attack have been reported in rather few studies so far. Sumatriptan--a selective serotonin 5HT1B/D receptor agonist, highly effective in terminating migraine attacks, decreases the elevated CGRP level back to normal. The aim of our study was to determine the effect of rizatriptan (a drug from a new generation of triptans) on CGRP release in migraine attacks. In 45 patients suffering from migraine attacks with and without aura, plasma CGRP levels were assessed during an attack twice: before treatment and two hours after rizatriptan administration. In the group under study the plasma CGRP level before treatment was significantly higher than that measured two hours after rizatriptan administration. The decrease in CGRP levels was associated with subsidence of the migraine attack. There was no difference between migraine patients with and without aura. These results suggest that triptans as serotonin 5HT1B/D receptor agonists decrease CGRP plasma concentration in migraine attacks.
authors.affiliation: Kliniki Neurologii Wojskowego Instytutu Medycyny Lotniczej w Warszawie.
authors.forename: Adam
authors.initials: A
authors.lastname: Stepień
authors.forename: Piotr
authors.initials: P
authors.lastname: Jagustyn
authors.forename: Elzbieta Anna
authors.initials: EA
authors.lastname: Trafny
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Widerkiewicz
mesh_terms: D000328:Adult; D015740:Calcitonin Gene-Related Peptide / Q000097:blood / Q000187:drug effects*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000188:drug therapy* / Q000378:metabolism*; D020325:Migraine with Aura / Q000188:drug therapy / Q000378:metabolism; D020326:Migraine without Aura / Q000188:drug therapy / Q000378:metabolism; D017366:Serotonin Receptor Agonists / Q000494:pharmacology*; D018170:Sumatriptan / Q000494:pharmacology*; D013997:Time Factors; D016896:Treatment Outcome; D014230:Triazoles / Q000494:pharmacology*; D014363:Tryptamines
chemical_list: D017366:Serotonin Receptor Agonists; D014230:Triazoles; D014363:Tryptamines; C093622:rizatriptan; D018170:Sumatriptan; D015740:Calcitonin Gene-Related Peptide